Download Syllabus for Clinical Aspects of Hematopoietic Stem Cell

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

page
1
page
2
page
3
Document related concepts
no text concepts found
Transcript 
Syllabus for Clinical Aspects of Hematopoietic Stem Cell Transplantation for OVMC Fellows
5/2017
Reading List:
ASCO-SEP Chapter on Hematopoietic Cell Transplantation
ASH-SAP Chapter on Clinical bone marrow and stem cell transplantation
ASH CME Quiz
Useful Texts/Resources:
Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care 2nd ed. 2015
Edition
Thomas' Hematopoietic Cell Transplantation, 2 Volume Set 5th Edition
Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians, 2nd edition 2nd Edition
Part One: Hematopoietic Transplantation
1. Overview of the Stem Cell Transplant Process
a. Which diseases are appropriate for HSCT?
b. Patient selection
c. Donor selection
d. Conditioning
e. GVHD Prophylaxis
2. Stem Cell Source
a. Peripheral Blood Stem Cells
b. Bone Marrow
3. Donor Selection
a. HLA Match – Matched Related, Matched Unrelated, Haploidentical
b. Female Donors
c. Donor-Specific Antibodies
d. Donor Age
e. Killer-like Immunoglobulin (KIR) Matching
4. Conditioning Regimens
a. Anti-Malignancy Effect
b. Immunosuppression
c. Use of TBI
d. Intensity & Toxicity
i. Myeloablative
ii. Reduce-Intensity
iii. Non-Myeloablative
5. GVHD Prophylaxis
a. Tacrolimus – Methotrexate
b. ATG
c. Post-transplant Cyclophosphamide
6. Day 0 – Engraftment
a. Definition of Engraftment
b. Delayed Engraftment / Primary Graft Failure
c. Regimen-Related Toxicity
i. Mucositis
ii. VOD
1. Risk factors for VOD
2. Diagnosis
3. Management
d. Sepsis / Infection
e. PRESS / Tacro toxicity
f. Fluid Overload
g. TMA
7. Engraftment – Day 100
a. Secondary Graft Failure
b. Viral Reactivation
c. Fungal Infection
d. Immunosuppression vs Immune Reconstitution
e. Acute GVHD
8. Management of Acute GVHD
a. Diagnosis
b. Grading
c. Management
9. CMV Reactivation
10. Chronic GVHD
a. Diagnosis
b. Grading
c. Management
11. Late Effects / Survivorship
a. Iron Overload
b. Infections
c. Relapse
i. Monitoring / MRD Testing
ii. Prophylaxis (TKI, hypomethylator)
iii. Donor Lymphocyte Infusions
iv. Second Allogeneic Transplant
d. Secondary Malignancies
Part Two: Transplantation for Specific Diseases
1. AML
a. Disease Risk Stratification
b. Role of Conditioning Intensity
c. GVM effect
2. ALL
a. Disease Risk Stratification & Impact of Blinatumomab and Inotuzumab
b. Role of Conditioning Intensity
c. GVM effect
3. CML
4. CLL?
5. MDS
6. Indolent Lymphoma
a. Role of CAR-T
b. Role of Targeted Therapies / Ibrutinib
7. DLBCL
8. Mantle Cell Lymphoma
9. Hodgkin Lymphoma
10. Multiple Myeloma
11. Aplastic Anemia
Related documents